On 18 October 2000, orphan designation (EU/3/00/006) was granted by the European Commission to Oxford GlycoSciences (UK) Ltd, United Kingdom, for 1,5-(butylimino)-1,5-dideoxy, D-glucitol for the treatment of Gaucher disease.
1,5-(butylimino)-1,5-dideoxy, D-glucitol for the treatment of Gaucher disease has been authorised in the EU as Zavesca since 20 November 2002.
The sponsorship was transferred to Actelion Registration Limited, United Kingdom, in March 2003.
|Disease / condition||
Treatment of Gaucher disease
|Date of decision||
|Orphan decision number||
Sponsor's contact details
BSI Building 13th floor
389 Chiswick High Road
Tel. + 44 (0)20 8987 3320
Fax + 44 (0)20 8987 3322
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;